Adriaan A. van Bodegraven

5.5k citations

116 papers · 3.6k indexed · h-index 32

Genetics top 1%
Surgery top 5%
Public Health, Environmental and Occupational Health top 2%
Epidemiology top 5%
Molecular Biology

Co-authors: Nanne K.H. de Boer Chris J. Mulder Muhammed Hadithi Peer de Graaf Chris J.J. Mulder Maarten Jacobs Margien L. Seinen Berrie Meijer
Topics: Inflammatory Bowel Disease (54 papers)Acute Lymphoblastic Leukemia research (42 papers)Microscopic Colitis (26 papers)
Cited by: Gastroenterology Genetics Public Health, Environmental and Occupational Health
Journals: Gastroenterology PLoS ONE Gut
Partner nations: Netherlands United States Germany

In The Last Decade

Adriaan A. van Bodegraven

112 papers receiving 3.5k citations

Peers

Countries citing papers authored by Adriaan A. van Bodegraven

Since Specialization

Citations

This map shows the geographic impact of Adriaan A. van Bodegraven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adriaan A. van Bodegraven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adriaan A. van Bodegraven more than expected).

Fields of papers citing papers by Adriaan A. van Bodegraven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adriaan A. van Bodegraven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adriaan A. van Bodegraven. The network helps show where Adriaan A. van Bodegraven may publish in the future.

Co-authorship network of co-authors of Adriaan A. van Bodegraven

This figure shows the co-authorship network connecting the top 25 collaborators of Adriaan A. van Bodegraven. A scholar is included among the top collaborators of Adriaan A. van Bodegraven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adriaan A. van Bodegraven. Adriaan A. van Bodegraven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Risk of Mild, Moderate, and Severe Infections in IBD patients – A prospective, multicentre observational cohort study (PRIQ) 2025 ·Journal of Crohn s and Colitis ·Ashkan Rezazadeh Ardabili,(unknown),(unknown),Mia Cilissen,(unknown),Zlatan Mujagic,(unknown),Laurents Stassen,Adriaan A. van Bodegraven,Dennis R. Wong,Björn Winkens,Daisy Jonkers,Mariëlle Romberg‐Camps,Marieke Pierik	2
2	Identification of spontaneous patient‐reported complaints related to perianal fistula in patients with Crohn's disease 2024 ·Colorectal Disease ·(unknown),Paul F. Vollebregt,Adriaan A. van Bodegraven,Danielle van der Horst,I. J. M. Han‐Geurts,R. J. F. Felt‐Bersma	0
3	Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency 2023 ·Metabolites ·(unknown),Luc J. J. Derijks,B.J.C. van den Bosch,(unknown),(unknown),Adriaan A. van Bodegraven,Dennis R. Wong	0
4	Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors 2023 ·Alimentary Pharmacology & Therapeutics ·(unknown),Ashkan Rezazadeh Ardabili,Mariëlle Romberg‐Camps,Björn Winkens,(unknown),Jessie M. Hulst,(unknown),Dániel Keszthelyi,Daisy Jonkers,Adriaan A. van Bodegraven,Marieke Pierik,Zlatan Mujagic	20
5	Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study 2023 ·Pharmaceutics ·(unknown),(unknown),Dennis R. Wong,Paul J. Boekema,Tessa E H Römkens,Lennard P. L. Gilissen,Adriaan A. van Bodegraven,Floris C. Loeff,Theo Rispens,Luc J. J. Derijks	9
6	Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease 2022 ·Alimentary Pharmacology & Therapeutics ·Ashkan Rezazadeh Ardabili,Steven Jeuring,Zlatan Mujagic,Liekele E. Oostenbrug,Mariëlle Romberg‐Camps,Daisy Jonkers,Adriaan A. van Bodegraven,Marieke Pierik	16
7	Replacement of Nitrite in Meat Products by Natural Bioactive Compounds Results in Reduced Exposure to N‐Nitroso Compounds: The PHYTOME Project 2021 ·Molecular Nutrition & Food Research ·Simone G. van Breda,(unknown),(unknown),Virág Sági‐Kiss,Gunter Kuhnle,Panagiotis Georgiadis,G. Saccani,G. Parolari,Roberta Virgili,Rashmi Sinha,(unknown),Yung Hung,Wim Verbeke,Ad Masclee,(unknown),Adriaan A. van Bodegraven,Theo M. de Kok	18
8	Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies 2019 ·Alimentary Pharmacology & Therapeutics ·Melek Simsek,(unknown),Carmen S. Horjus,(unknown),Birgit I. Lissenberg‐Witte,(unknown),Matthijs van Luin,Margien L. Seinen,Chris J. Mulder,Dennis R. Wong,Nanne K.H. de Boer,Adriaan A. van Bodegraven	29
9	Long-Term Follow-Up of Transgender Women After Secondary Intestinal Vaginoplasty 2016 ·The Journal of Sexual Medicine ·Wouter B. van der Sluis,Mark‐Bram Bouman,Nanne K.H. de Boer,Marlon E. Buncamper,Adriaan A. van Bodegraven,Andra Neefjes‐Borst,Baudewijntje P.C. Kreukels,W. J. H. J. Meijerink,Margriet G. Mullender	78
10	Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review 2016 ·World Journal of Gastroenterology ·Berrie Meijer,Chris J. Mulder,Godefridus J. Peters,Adriaan A. van Bodegraven,Nanne K.H. de Boer	51
11	Characterization of Microbiota in Children with Chronic Functional Constipation 2016 ·PLoS ONE ·Tim G. J. de Meij,E. F. J. de Groot,Anat Eck,Andries E. Budding,C. M. F. Kneepkens,Marc A. Benninga,Adriaan A. van Bodegraven,Paul H. M. Savelkoul	95
12	Morphological spectrum of neovaginitis in autologous sigmoid transplant patients 2015 ·Histopathology ·Wouter B. van der Sluis,Andra Neefjes‐Borst,Mark‐Bram Bouman,W. J. H. J. Meijerink,Nanne K.H. de Boer,Margriet G. Mullender,Adriaan A. van Bodegraven	13
13	Refractory celiac disease and EATL patients show severe malnutrition and malabsorption at diagnosis 2015 ·Clinical Nutrition ·Nicolette Wierdsma,Petula Nijeboer,M.A.E. de van der Schueren,(unknown),Adriaan A. van Bodegraven,Chris J. Mulder	23
14	Increased IgA Glycoprotein-2 Specic Antibody Titres in Refractory Celiac Disease 2014 ·Journal of Gastrointestinal and Liver Diseases ·(unknown),Sjoerd F. Bakker,Adriaan A. van Bodegraven,Ingrid M. W. van Hoogstraten,Kyra A. Gelderman,Gerd Bouma,Chris J. Mulder,B. Mary E. von Blomberg,Hetty J. Bontkes	18
15	Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation 2013 ·Gut ·Adriaan A. van Bodegraven,Nathalie Bravenboer,Birgit I. Lissenberg‐Witte,Gerard Dijkstra,C. Janneke van der Woude,(unknown),Maurice G. Rüssel,Bas Oldenburg,Marieke Pierik,Jan C. Roos,R. A. van Hogezand,Vincent K. Dik,(unknown),J. C. Netelenbos,(unknown),Daniël W. Hommes,Paul Lips	18
16	Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population 2008 ·World Journal of Gastroenterology ·Muhammed Hadithi,Marcel Cazemier,Gerrit A. Meijer,Elisabeth Bloemena,(unknown),Chris J. Mulder,S. G. M. Meuwissen,A. S. Peña,Adriaan A. van Bodegraven	27
17	Paradoxical Elevated Thiopurine S-Methyltransferase Activity After Pancytopenia During Azathioprine Therapy: Potential Influence of Red Blood Cell Age 2008 ·Therapeutic Drug Monitoring ·Nanne K.H. de Boer,Adriaan A. van Bodegraven,Peer de Graaf,R.W.M. van der Hulst,Lida Zoetekouw,André B. P. Kuilenburg	13
18	Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients 2007 ·Digestive and Liver Disease ·Nanne K.H. de Boer,Pieter E. Zondervan,Lennard P. L. Gilissen,G. den Hartog,B. D. Westerveld,Luc J. J. Derijks,Elisabeth Bloemena,L.G.J.B. Engels,Adriaan A. van Bodegraven,Chris J. Mulder	42
19	A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis 2005 ·International Journal of Immunogenetics ·Michelle E A Borm,Adriaan A. van Bodegraven,Chris J. Mulder,Georg Kraal,(unknown)	72
20	On the limitation of 6‐tioguaninenucleotide monitoring during tioguanine treatment 2005 ·Alimentary Pharmacology & Therapeutics ·Nanne K.H. de Boer,Peer de Graaf,Abraham J. Wilhelm,Chris J. Mulder,Adriaan A. van Bodegraven	21

About Adriaan A. van Bodegraven

Adriaan A. van Bodegraven is a scholar working on Genetics, Gastroenterology and Public Health, Environmental and Occupational Health, having authored 116 papers that have together received 3.6k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (54 papers), Acute Lymphoblastic Leukemia research (42 papers) and Microscopic Colitis (26 papers). The work is most often cited by research in Gastroenterology (546 citations), Genetics (1.3k citations) and Public Health, Environmental and Occupational Health (887 citations). Adriaan A. van Bodegraven has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Nanne K.H. de Boer, Chris J. Mulder, Muhammed Hadithi, Peer de Graaf, Chris J.J. Mulder, Maarten Jacobs, Margien L. Seinen, Berrie Meijer, Bindia Jharap and G. Dimitri N. Heine. Their work appears in journals such as Gastroenterology, PLoS ONE and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact